Market Closed -
Nasdaq Stockholm
16:29:30 10/05/2024 BST
|
5-day change
|
1st Jan Change
|
1.722
SEK
|
+17.14%
|
|
+13.14%
|
-62.11%
|
Fiscal Period: December |
2018
|
2019
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
166.9
|
96.52
|
344.2
|
168.9
|
208.7
|
208.7
|
-
|
Enterprise Value (EV)
1 |
146.5
|
85.25
|
344.2
|
73.78
|
370.4
|
208.7
|
208.7
|
P/E ratio
|
-
|
-
|
-7.48
x
|
-2.37
x
|
-9.28
x
|
-2.46
x
|
4.31
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
466
x
|
30
x
|
-
|
224
x
|
358
x
|
-
|
3.03
x
|
EV / Revenue
|
466
x
|
30
x
|
-
|
224
x
|
358
x
|
-
|
3.03
x
|
EV / EBITDA
|
-
|
-
|
-
|
-3.28
x
|
-5.97
x
|
-2.57
x
|
3.88
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
19,054
|
20,983
|
56,144
|
79,308
|
121,186
|
121,186
|
-
|
Reference price
2 |
8.760
|
4.600
|
6.130
|
2.130
|
1.722
|
1.722
|
1.722
|
Announcement Date
|
22/02/19
|
21/02/20
|
18/02/22
|
21/02/23
|
23/02/24
|
-
|
-
|
Fiscal Period: December |
2018
|
2019
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
0.358
|
3.216
|
-
|
0.753
|
1.035
|
-
|
68.9
|
EBITDA
1 |
-
|
-
|
-
|
-51.57
|
-62.04
|
-81.3
|
53.8
|
EBIT
1 |
-45.92
|
-35.65
|
-
|
-51.93
|
-65.04
|
-81.3
|
53.8
|
Operating Margin
|
-12,827.09%
|
-1,108.61%
|
-
|
-6,896.95%
|
-6,284.25%
|
-
|
78.08%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-
|
-52.48
|
-64.89
|
-81.3
|
53.8
|
Net income
1 |
-
|
-
|
-45.69
|
-52.48
|
-64.89
|
-81.3
|
53.8
|
Net margin
|
-
|
-
|
-
|
-6,969.99%
|
-6,269.47%
|
-
|
78.08%
|
EPS
2 |
-
|
-
|
-0.8200
|
-0.9000
|
-0.4900
|
-0.7000
|
0.4000
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
22/02/19
|
21/02/20
|
18/02/22
|
21/02/23
|
23/02/24
|
-
|
-
|
Fiscal Period: December |
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
---|
Net sales
1 |
-
|
-
|
-
|
0.443
|
-
|
-
|
-
|
EBITDA
1 |
-17.1
|
-18.23
|
-10.48
|
-18.99
|
-20.3
|
-20.3
|
-20.3
|
EBIT
1 |
-17.19
|
-18.32
|
-10.55
|
-18.99
|
-20.3
|
-20.3
|
-20.3
|
Operating Margin
|
-
|
-
|
-
|
-4,285.78%
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-17.5
|
-18.19
|
-10.73
|
-18.47
|
-20.3
|
-20.3
|
-20.3
|
Net income
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.2200
|
-0.2300
|
-0.1300
|
-0.2300
|
-0.2000
|
-0.1700
|
-0.1700
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19/05/23
|
18/08/23
|
17/11/23
|
23/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2018
|
2019
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
20.4
|
11.3
|
-
|
95.1
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
22/02/19
|
21/02/20
|
18/02/22
|
21/02/23
|
23/02/24
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| -62.11% | 19.26M | | +3.91% | 109B | | +10.87% | 105B | | +1.28% | 22.25B | | -13.14% | 22.09B | | -7.05% | 18.68B | | -38.36% | 17.58B | | -10.66% | 16.85B | | +3.75% | 13.76B | | +36.70% | 12.46B |
Bio Therapeutic Drugs
|